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Introduction
The importance of epigenetic regulation in development such as 
that of stem cells and in diseases such as cancer has been in-
creasingly recognized (Sims et al., 2003; Niwa, 2007). Whether 
the  chromatin  adopts  a  condensed  or  open  configuration  is 
jointly governed by histone modification and DNA methylation, 
and this in turn controls gene expression. Histone methylation 
at lysine (K) residues has been associated with gene activation 
(e.g., K4 of histone H3) or repression (e.g., K9 and K27 of his-
tone H3; Sims et al., 2003). Although much has been learned 
about chromatin control in embryonic and hematopoietic stem 
cells (Niwa, 2007; Cui et al., 2009), epigenetic mechanisms   
underlying the self-renewal and differentiation of tissue-specific 
epithelial stem/progenitor cells remain poorly understood.
The  identification  and  characterization  of  multipotent 
mammary stem/progenitor cells (Shackleton et al., 2006; Stingl 
et al., 2006) make the mammary gland an excellent model to 
study both genetic and epigenetic control of epithelial stem cell 
development and homeostasis. Such study holds the potential to 
greatly enhance our understanding of how breast cancer cells 
arise. Recent evidence points to an important role for the epi-
genetic silencer Bmi1 in both mammary stem cells and their 
more committed progeny (Pietersen et al., 2008). To date, little 
is known about epigenetic activators that control the self- 
renewal and differentiation of mammary stem/progenitor cells.
The Pygopus (Pygo) family of proteins contains a highly 
conserved C-terminal plant homeo domain (PHD) often found in 
chromatin regulatory factors (Bienz, 2006). Drosophila melano-
gaster Pygo, which is a prototype of the family, was identified as a 
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ecent studies have unequivocally identified multipotent 
stem/progenitor cells in mammary glands, offering a 
tractable model system to unravel genetic and epi­
genetic regulation of epithelial stem/progenitor cell develop­
ment and homeostasis. In this study, we show that Pygo2, a 
member of an evolutionarily conserved family of plant   
homeo domain–containing proteins, is expressed in embry­
onic and postnatal mammary progenitor cells. Pygo2 defi­
ciency, which is achieved by complete or epithelia­specific 
gene ablation in mice, results in defective mammary mor­
phogenesis and regeneration accompanied by severely 
compromised expansive self­renewal of epithelial progeni­
tor cells. Pygo2 converges with Wnt/­catenin signaling on 
progenitor cell regulation and cell cycle gene expression, 
and loss of epithelial Pygo2 completely rescues ­catenin–
induced mammary outgrowth. We further describe a novel 
molecular function of Pygo2 that is required for mammary 
progenitor cell expansion, which is to facilitate K4 trimethyl­
ation of histone H3, both globally and at Wnt/­catenin 
target loci, via direct binding to K4­methyl histone H3 and 
recruiting histone H3 K4 methyltransferase complexes.
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ducts, with TEB inner body and outer cap cells giving rise to lu-
minal and basal/myoepithelial cells, respectively (Ball, 1998; 
Kenney et al., 2001; Woodward et al., 2005). Strong Pygo2 sig-
nals were observed in all body and some cap cells of the TEB in 
pubertal mammary glands (Fig. 1 D). As development proceeded 
and cells left the ductal tips, Pygo2 expression became down- 
regulated (Fig. 1 E, arrow) such that in mature glands, nuclear 
Pygo2 was barely detectable (not depicted). During pregnancy, 
small structures bud off the ductal compartment and differentiate 
to form an expanded lobuloalveolar compartment composed of 
basal myoepithelium and secretory luminal epithelium (Fig. 1 F; 
Hennighausen and Robinson, 2001). Pygo2 expression became 
prominent again, particularly in the developing alveolar structures 
(Fig. 1 G). Together, these results demonstrate that Pygo2 is ex-
pressed in developmental mammary stem/progenitor cells, and its 
presence correlates with active proliferation of these cells.
Epithelial Pygo2 is required for mammary 
gland morphogenesis
To ask whether Pygo2 is required for mammary development, we 
first examined embryonic mammogenesis in Pygo2
/ mice. 
Whole-mount skin preparations from Pygo2
/ female embryos 
revealed mammary defects with a variable penetrance ranging 
from absence of any rudiment to impaired elongation and branch-
ing of the bud/sprout (Fig. 2, A and B). Most often, glands 1, 2, 
and 3 were visibly absent, and if present, never branched. Even in 
the least affected gland 4, branching morphogenesis was less ad-
vanced than in the wild type. The differential effect of Pygo2 de-
letion is in keeping with the previous finding that different pairs of 
mammary glands respond differently to the same genetic muta-
tions (Veltmaat et al., 2006).
To investigate the importance of epithelial Pygo2 in postnatal 
mammary development, we generated Pygo2 skin/mammary   
epithelia–specific knockout (SSKO) mice by crossing a “floxed” 
Pygo2 allele (Li et al., 2007) with transgenic mice expressing Cre 
under the K14 promoter (K14-Cre; Andl et al., 2004). The specific-
ity and efficacy of K14-Cre was demonstrated by -galactosidase 
expression in mammary placode and surrounding surface ectoderm 
(Fig. 2 C) as well as throughout the basal and luminal compartments 
of postnatal virgin mammary glands (Fig. 2 D and not depicted) of 
K14-Cre/Rosa26R  mice.  Rosa26R  is  a  reporter  line  containing 
loxP-flanked lacZ that can be activated by Cre-mediated recombina-
tion (Zambrowicz et al., 1997). PCR of tissue genomic DNAs iso-
lated from Pygo2 SSKO (i.e., K14-Cre/Pygo2
flox/) mice confirmed 
skin epithelia–specific recombination at the Pygo2 locus (Fig. 2 E). 
Although residual Pygo2-expressing cells were occasionally seen, a 
vast majority of mammary epithelial cells (MECs) in virgin SSKO 
females lacked detectable Pygo2 protein (Fig. 2 F).
Similar to Pygo2
/ animals, mammary glands 1 and 2 in 
SSKO newborns were developmentally impaired (unpublished 
data). In contrast, gland 4 was indistinguishable from wild type 
at the newborn stage (unpublished data), allowing us to assess the 
role of Pygo2 in its postnatal development. The most remarkable 
defect was a lack of prominent TEB structures in 3-wk-old Pygo2 
SSKO females (Fig. 2 G, arrows). At 6 wk, ductal elongation 
was significantly delayed (Fig. 2 H), whereas by 9 wk, SSKO 
glands often contained fewer branches and lateral buds than control 
highly  specific  downstream  component  of  canonical  Wingless 
(Wg; Drosophila Wnt) signaling (Belenkaya et al., 2002; Kramps 
et al., 2002; Parker et al., 2002; Thompson et al., 2002). Published 
data support two nonmutually exclusive models regarding the bio-
chemical function of Pygo proteins: (1) they are recruited to   
-catenin–lymphoid enhancer factor complex, which are nuclear 
effectors of Wg/Wnt signaling, via the adapter protein Legless/
BCL9 and act as a transcriptional coactivator of the complex;   
(2) they facilitate nuclear retention of -catenin (for review see   
Jessen et al., 2008). Of the two mammalian Pygo homologues, 
Pygo2 is more broadly expressed and functionally important than 
Pygo1 (Li et al., 2007; Schwab et al., 2007). Pygo2 is required for 
the proper development of multiple tissues, whereas additional de-
letion of Pygo1 does not appear to aggravate the Pygo2 phenotype 
(Li et al., 2007; Schwab et al., 2007; Song et al., 2007; Nair et al., 
2008). In contrast to Drosophila Pygo, Pygo2 function in the two 
most extensively characterized Pygo2-requiring tissues, eye and 
testis, is independent of Wnt/-catenin (Song et al., 2007; Nair   
et al., 2008; for review see Jessen et al., 2008). As such, genetic 
evidence for a functional interaction between mammalian Pygo 
genes and Wnt/-catenin signaling is currently lacking.
In this work, we combine mouse genetics with biochemical 
approaches to study the function of Pygo2 in mammary stem/ 
progenitor cells. We show that Pygo2 regulates mammary develop-
ment by cell-intrinsically controlling the expansive self-renewal 
of epithelial progenitor cells. We provide evidence that Pygo2 
regulates the expression of Wnt/-catenin target genes, including 
those involved in cell cycle G1–S progression, and that loss of 
Pygo2 rescues -catenin overexpression–induced mammary out-
growth. We present in vitro and in vivo data that Pygo2 facilitates 
the trimethylation of histone H3 K4 by binding to K4-methyl his-
tone H3 and recruiting histone H3 K4 methyltransferase (HMT) 
complexes to bulk chromatin and Wnt target loci and that this 
chromatin function of Pygo2 is required for optimal expansive 
self-renewal of mammary progenitor cells.
Results
Pygo2 expression is enriched  
in developmental mammary  
stem/progenitor cells
To explore the function of Pygo2, we first examined its expression 
in embryonic and postnatal mammary glands using a polyclonal 
antibody against Pygo2 (Li et al., 2007). Mammary placode, rep-
resenting a field of developmental mammary progenitor cells, 
forms between embryonic day (E) 10.5 and E11.5, and progresses 
through bud and sprout stages to give rise to a rudimentary mam-
mary tree by birth (Fig. 1 A; Veltmaat et al., 2003). Nuclear Pygo2 
protein was detected in placodal epithelium (not depicted) but   
became more prominent in actively growing mammary buds 
(Fig. 1 B). A few surrounding mammary mesenchymal cells also 
expressed Pygo2 (Fig. 1 B, arrowhead). After birth, the mammary 
gland enters a relatively quiescent stage but then expands rapidly 
via elongation and branching at around 3–7 wk of age, culminat-
ing in a mature gland by 10–12 wk (Fig. 1 C). Ductal morpho-
genesis is driven by the active proliferation of mammary progenitor 
cells that reside at the tip, or terminal end bud (TEB), of elongating 813 PYGO2 IN BREAST PROGENITOR CELLS • Gu et al.
glands using known markers of multipotent mammary stem 
cells, namely Lin
CD24
+CD29
High (Shackleton et al., 2006).   
An  approximately  twofold  reduction  in  Lin
CD24
+CD29
High 
cells was consistently observed in the mutant (Fig. 3 A). The 
Lin
CD24
+CD29
High  population  includes  basally  localized 
myoepithelial cells. Therefore, we examined the expression of 
K6, a marker of multi/bipotent early progenitor cells that are 
likely immediate progeny of the stem cells (Smith et al., 1990; 
Grimm et al., 2006; Stingl et al., 2006). At the ages (3–9 wk   
after birth) when K6 expression was readily observed in control 
glands, there was a significant reduction to near absence of K6
+ 
cells in mutant TEBs and ducts (Fig. 3 B). A reduced presence 
of K6
+ cells was also evident in Pygo2-deficient embryonic 
mammary gland, but this reduction was less remarkable than in 
the adult (Fig. S2 A). The progressive loss of K6
+ progenitor 
glands (Fig. S1 A). Mammary defects persisted during pregnancy 
and lactation, as shown by apparently reduced alveolar formation 
and reduced milk production in some SSKO females (Fig. S1,   
B–D). In contrast, mammary gland morphology and function   
in Pygo2
flox/ littermates were comparable with the wild type 
(Fig. S1 D and not depicted). Collectively, these results demonstrate 
that Pygo2 functions at least in part in the mammary epithelium to 
regulate critical aspects of mammogenesis, including elongation 
and branching of embryonic and postnatal mammary glands.
Pygo2 controls the expansion of  
mammary progenitor cells but is dispensable 
for their differentiation
To explore whether mammary stem cells are affected, we first 
performed FACS analysis of adult virgin control and SSKO 
Figure 1.  Pygo2 expression in mammary epithelial progenitor cells. (A, C, and F) Sketch diagrams showing anatomical features of embryonic (A), 
pubertal (C), and pregnant (F) mammary glands. (B, left) Strong Pygo2 expression in E15.5 mammary bud, particularly in the bulb region (asterisk). The 
inset is an enlarged image showing nuclear localization of Pygo2. The white dashed lines indicate basement membrane separating epithelial and mesen-
chymal compartments. The absence of signal in Pygo2
/ mammary bud (right) confirms antibody specificity. The arrowhead points to Pygo2-expressing 
mesenchymal cells. (D) Pygo2 expression in cap (outlined by keratin 14
+ or K14
+; arrow) and body cells (indicated by an asterisk) of TEBs from 3-wk-old 
females. (E) Pygo2 expression in 6-wk-old mammary epithelium. Note the reduced Pygo2 expression as cells leave the TEB (arrow). (G) Ubiquitous Pygo2 
expression in lobuloalveolar cells of 18.5-d pregnant mammary glands. The planes of sections for D/E and G are indicated by the dashed lines in C and F, 
respectively. WT, wild type. Bars: (B) 30 µm; (D and E) 25 µm; (G) 50 µm.JCB • VOLUME 185 • NUMBER 5 • 2009   814
control mice. Under the dilutions tested, Pygo2-deficient cells 
showed a nonstatistically significant decrease in the rate of suc-
cessful transplantation (take rate) but displayed significantly 
less extensive mammary outgrowth (percent of fat pad filled) 
when  compared  with  contralaterally  injected  wild-type  cells 
(Fig. 3 D). We also seeded MECs at clonal densities on Matrigel 
to determine their differentiation potential in vitro. Control cells 
produced many colonies: some were large and composed of 
solid and lumen-containing structures reminiscent of those 
formed by isolated multipotent stem and/or early progenitor 
cells (Stingl et al., 2006), whereas others were small, with a dis-
tinct acinar morphology reminiscent of those formed by more 
differentiated progenitor cells (Fig. 3 E and not depicted).   
In SSKO mutant culture, the number of large, solid colonies was 
reduced (unpublished data). Importantly, many control colonies 
contained K6
+ cells, whereas the number of both K6
+ colonies 
and K6
+ cells per positive colony were greatly reduced in the 
cells is consistent with an expansion defect. In contrast, no re-
duction was seen for ER
+/PR
+ hormone-sensing cells (Fig. 3 C 
and Fig. S2 B; Sleeman et al., 2007). Moreover, the expression 
of GATA-3 and TCF4, two transcription factors normally ex-
pressed in luminal epithelial cells (Barker et al., 1999; Kouros-
Mehr et al., 2006; Asselin-Labat et al., 2007), and of NKCC1, 
a ductal luminal epithelial marker (Moore-Hoon and Turner, 
1998; Miyoshi et al., 2001), was comparable between control 
and SSKO mammary glands (Fig. S2, C–E). Finally, gene ex-
pression analysis revealed increased mRNA levels of luminal 
keratin  and  alveolar  differentiation  markers,  including  K8, 
K18, K19, and -casein (Fig. S2, F and G), likely reflecting an 
imbalance in the numbers of mature luminal cells versus stem/
progenitor cells.
To investigate the effect of Pygo2 deficiency on mammary 
stem/progenitor  cell  activity,  we  performed  limiting  dilution 
transplantations using primary MECs isolated from SSKO and 
Figure 2.  Embryonic and postnatal mammary phenotypes of Pygo2-deficient mice. (A) Whole-mount preparations of carmine-stained skins of E18.5 wild-
type (WT; top) and Pygo2
/ (bottom) embryos showing select individual mammary glands (MG). (B) Summary of results obtained on all ten glands from 
multiple mutant embryos (n = 4). The mean branching point is calculated to be 3.25 ± 0.63 and 6.5 ± 1.04 for mutant and wild type, respectively (asterisk; 
P = 0.04). (C) Whole-mount LacZ-stained skin preparation of an E11.5 K14-Cre/Rosa26R embryo. A transversal section of placode 3 (arrow) is shown at the 
bottom. (D) LacZ-stained cross sections (counterstained with hematoxylin and eosin) through mammary duct (top) and TEB (bottom) of a 3-wk-old K14-Cre/ 
Rosa26R female. (E) Genomic PCR of Pygo2 alleles showing recombination in epidermis but not dermis or other tissues. Co, colon; De, dermis; Ep, epidermis; 
He, heart; In, intestine; Li, liver; Lu, lung; St, stomach. The plus and minus signs denote the controls for PCR. (F) Absence of Pygo2 in ductal epithelia and TEBs 
(insets) of virgin SSKO mammary glands. (G and H) Carmine red–stained whole-mount preparations of mammary gland 4 from 3-wk-old (n = 4; G) and 6-wk-old 
(n = 3; H) females. Note the absence of TEB structures (short arrows in G) and the defective ductal elongation (marked by long arrows in H) in mutants. The 
control genotypes shown are K14-Cre/Pygo2
flox/+ (F and G) and Pygo2
flox/+ (G). Bars: (A) 112 µm; (C) 30 µm; (D and F) 25 µm; (G) 107 µm; (H) 937 µm.815 PYGO2 IN BREAST PROGENITOR CELLS • Gu et al.
Pygo2 regulates MEC cell cycle progression
Active proliferation drives the expansive self-renewal of stem/
progenitor cells during development. Therefore, we compared 
the proliferative activity of developmental progenitor cells in 
mutant (Fig. 3 E). Collectively, our results demonstrate that 
Pygo2 deletion adversely affects the expansion of mammary 
stem/progenitor cells while leaving the biochemistry and differ-
entiation of mammary epithelium largely intact.
Figure 3.  Pygo2 SSKO mammary epithelium contains fewer stem/progenitor cells. (A) Results of FACS analysis revealing a decreased number of 
Lin
CD24
+CD29
High cells in 10-wk-old Pygo2-deficient mammary glands. Representative FACS profiles from a single pair are shown on the left, and mean 
values from three different pairs are shown on the right. (B) Reduced presence of K6
+ progenitor cells in 8-wk-old Pygo2-deficient mammary duct and ductal   
termini (insets). (C) ER expression is not affected by Pygo2 loss. (D) Representative results from limiting dilution transplantations of MECs derived from   
9–12-wk-old control or Pygo2 SSKO (n = 6) mice. (E) Reduced colony formation and K6 expression in Matrigel culture of MECs isolated from 8-wk-old 
SSKO mice. A quantitative analysis (right) reveals a statistically significant reduction in the number of K6
+ colonies and K6
+ cells per positive colony. The 
control genotypes shown are two Pygo2
flox/+ and one wild type (A), Pygo2
flox/+ (B), K14-Cre/Pygo2
flox/+ (C), four Pygo2
flox/+ and two K14-Cre/Pygo2
flox/+ 
(D), and two K14-Cre/Pygo2
flox/+ and one Pygo2
flox/+ (E). (A and E) Error bars represent standard deviation. Bars: (B and C) 25 µm; (E) 37.5 µm.JCB • VOLUME 185 • NUMBER 5 • 2009   816
cycle progression directly, we turned to siRNA knockdown to 
acutely deplete Pygo2 in MCF10A cells, an immortal, nontrans-
formed human MEC line which possess mammary progenitor 
cell activity (Fig. S3 B) and which expresses progenitor-associated 
genes (Neve et al., 2006). Efficient knockdown of Pygo2 was 
achieved and could be maintained in culture for >96 h (unpub-
lished data). When cells were cultured at a high density, a sig-
nificant decrease in growth rate was observed when Pygo2 was 
depleted (Fig. 4 B). When plated at a clonal density, a significant 
decrease in the number and size of colonies was observed for 
Pygo2-depleted cells (Fig. 4 C). FACS analysis of DNA content 
revealed a larger G1 population and a smaller S/G2/M popula-
tion in Pygo2-depleted high-density culture than control (Fig. 4 D). 
These findings suggest that Pygo2 cell-intrinsically regulates 
normal and Pygo2
/ mammary buds. Buds from Pygo2
/ em-
bryos contained fewer BrdU-incorporating cells than their wild-
type counterparts (Fig. 4 A), indicating that Pygo2-deficient 
progenitor cells are less proliferative. There was no significant 
change in the number of apoptotic cells, as visualized by TUNEL 
staining (unpublished data). We also analyzed pregnant females 
and observed a reduction in alveologenesis-associated prolifer-
ation in a subset of Pygo2-deficient mammary glands (Fig. S1 E). 
Based on these findings, we surmise that Pygo2 regulates the pro-
liferation but not survival of mammary epithelial progenitor cells.
In vitro passaging of MECs derived from Pygo2 SSKO 
mice resulted in a culture population composed mostly of 
Pygo2-positive cells (Fig. S3 A), suggesting that residual Pygo2 
expression confers a selective growth advantage. To analyze cell 
Figure 4.  Loss of Pygo2 leads to reduced mammary epithelial proliferation and compromised G1–S transition. (A) Immunohistochemical detection of BrdU 
incorporation in mammary buds of E15.5 control and Pygo2
/ embryos. The BrdU-labeling index, calculated as the percent of BrdU-positive cells per 
total number of cells in mammary buds, is shown on the right. P < 0.001. The dashed lines indicate the basement membranes. WT, wild type. (B) Reduced 
growth of Pygo2-depleted MCF10A cells in high-density culture. (C) Reduced colony formation by Pygo2-depleted cells. (D) Cell cycle analysis of control 
and Pygo2-depleted cells. (E) Altered expression of cell cycle genes in Pygo2-depleted cells. mRNAs were collected 3 d after siRNA transfection and quanti-
fied by quantitative RT-PCR. (A–C and E) Error bars represent standard deviation. Bars, 20 µm.817 PYGO2 IN BREAST PROGENITOR CELLS • Gu et al.
mammary rudiments of E11.5 to E15.5 Pygo2
+/+/BAT-gal em-
bryos, whereas expression was significantly reduced in Pygo2
//
BAT-gal littermates (Fig. 5, A and B; and not depicted). The ex-
tent of reduction was greatest in mammary buds 2 and 3, corre-
lating with their most severe morphological defects. We also 
examined the expression of Lef1, an endogenous Wnt/-catenin 
target (Hovanes et al., 2001; Filali et al., 2002). Normally, Lef1 is 
expressed in the developing mammary epithelium (Mailleux   
et al., 2002); however, in Pygo2
/ mammary buds, its mRNAs 
were barely detectable (Fig. 5 C). In contrast, the expression of 
another early mammary epithelial marker, Wnt10b (Veltmaat et al., 
2004), was unaffected (Fig. S4). Reduced Lef1 mRNA expression 
was also seen in postnatal mammary glands of Pygo2 SSKO mice 
(Fig. 5 D). Collectively, these results demonstrate that Pygo2 is 
required in vivo for gene expression downstream of Wnt/ 
-catenin signaling.
To test the genetic interaction between Pygo2 and Wnt/ 
-catenin signaling, we first examined postnatal mammary mor-
phogenesis in two mouse models in which Wnt/-catenin 
signaling is aberrantly activated. K14-N–-catenin transgenic 
mammary progenitor cell proliferation by promoting cell cycle 
G1–S progression. Consistent with this function, we observed 
reduced mRNA expression of c-Myc and cyclin D1, which nor-
mally promotes G1–S transition, and increased expression of 
p21
WAF1/cip1 (referred to as p21 from here on), which is an inhibi-
tor of cyclin-dependent kinase required for G1–S transition, in 
Pygo2-depleted cells (Fig. 4 E).
Decreased Wnt/-catenin target gene 
expression and rescue of -catenin 
overexpression–induced mammary 
outgrowth in Pygo2-deficient animals
The mammary stem/progenitor cell phenotype of Pygo2-deficient 
mice  mirrors  that  in Wnt-activating  mutants  (Li  et  al.,  2003; 
Shackleton et al., 2006), raising the possibility that Pygo2 is in-
volved in Wnt/-catenin signaling in mammary epithelium. To 
address this, we first generated Pygo2
/ animals carrying a trans-
genic BAT-gal Wnt reporter gene that expresses -galactosidase 
at sites where canonical Wnt signaling is active (Maretto et al., 
2003). Strong -galactosidase expression was seen persistently in 
Figure 5.  Pygo2 is required for Wnt/-catenin target gene expression in mammary epithelium. (A and B) Whole-mount LacZ staining of Pygo2 wild-type 
(WT; top) and deficient (bottom) BAT-gal embryos at E11.5 (A) and E15.5 (B). Numbers (2 and 3) next to the arrows indicate mammary buds 2 and 3. Corre-
sponding sections of the boxed areas are shown on the right. Closed and open arrows indicate externally visible and invisible mammary glands, respectively. 
(C) Whole-mount in situ hybridization for Lef1 on E13.5 wild-type and mutant embryos. (D) Results of quantitative RT-PCR showing reduced Lef1 expression 
in Pygo2 SSKO mammary glands (n = 3). The error bar represents standard deviation. Bars: (A) 195 µm; (B) 315 µm; (C) 900 µm; (insets) 20 µm.JCB • VOLUME 185 • NUMBER 5 • 2009   818
(Fig. 6, D and E). These findings provide in vivo evidence that 
Pygo2 interacts with Wnt/-catenin signaling to regulate mam-
mary epithelial morphogenesis.
Pygo2 binds to K4 di- and trimethylated 
histone H3, and this binding is important 
for mammary progenitor cell proliferation
Pygo2 contains a PHD, which has recently emerged as a recog-
nition motif of K4 trimethylated histone H3 (H3K4me3; Pena 
et al., 2006; Shi et al., 2006; Taverna et al., 2006; Wysocka   
et al., 2006). Sequence alignment revealed that Pygo2 PHD 
contains several amino acids (for example, tryptophan [W] 352) 
that are present at similar positions in PHD of the H3K4me3-
binding ING2 (Fig. 7 A). We generated and purified bacterially 
expressed Pygo2 PHD fused to GST (GST–Pygo2 PHD) and 
performed pull-down assays to examine its binding to native 
histones purified from calf thymus. Specific binding of GST–
Pygo2 PHD but not GST to histones was observed (Fig. 7 B), 
mice express a stabilized form of -catenin under the K14 pro-
moter (Gat et al., 1998). Compared with wild-type littermates, 
transgenic virgin females showed precocious branching and lat-
eral bud formation (Fig. 6 A). Moreover, at an age (>12 wk) when 
wild-type glands no longer contained an appreciable number of 
K6
+ cells, K14-N–-catenin transgenic mammary glands often 
displayed a persistent existence of such cells (Fig. 6 B). Pro-
longed accumulation of K6
+ cells was also observed when 
Cby1, a negative regulator of nuclear -catenin (Takemaru   
et al., 2003; Voronina et al., 2009), was deleted (Fig. 6 C). We 
note that these phenotypes are not fully penetrant; instead, there 
is an inverse correlation between increased K6
+ cells and mor-
phological  overgrowth  (unpublished  data),  implying  that  K6
+ 
cells are a transient population. To examine whether loss of Pygo2 
rescues K14-N–-catenin–induced mammary overgrowth, we 
generated K14-Cre/Pygo2
flox//K14-N–-catenin females. Mam-
mary glands from these mice were indistinguishable from con-
trol littermates and no longer showed precocious outgrowth 
Figure 6.  Loss of Pygo2 rescues the mammary outgrowth phenotype of K14-N–-catenin mice. (A) Whole-mount carmine staining of mammary glands 
from 12-wk-old wild-type (WT) and K14-N–-catenin (n = 5) females. (B and C) Persistent K6 expression in adult glands from K14-N–-catenin (12 wk 
old; B, right) and Cby1
/ (39 wk old; C, right) mice. The basal compartment is outlined by K14 staining. The insets show images of TEBs. (D) Whole-mount 
carmine-stained skin of 12-wk-old K14-N–-catenin and K14-N–-catenin/Pygo2 SSKO (n = 4) littermates. (E) Quantitative analysis of branch points. 
Error bars represent standard deviation. -cat, -catenin. Bars: (A and D) 500 µm; (B and C) 25 µm.819 PYGO2 IN BREAST PROGENITOR CELLS • Gu et al.
A reduction in H3K4me2 level also occurred, whereas the levels 
of H3K4me1, H3K9me3, and H3K27me3 were not significantly 
affected (Fig. 8 B). Supporting these cell culture experiments, 
we detected a dramatically reduced level of H3K4me3 in Pygo2 
SSKO mammary glands (Fig. 8 C). To examine whether reduced 
H3K4me3 occurs at specific Wnt/-catenin target loci, we per-
formed chromatin immunoprecipitation (ChIP) analysis on c-Myc 
enhancer (He et al., 1998; van de Wetering et al., 2002) and 
Lef1 promoter (Hovanes et al., 2001) using primers that am-
plify regions encompassing lymphoid enhancer factor/T cell 
factor–binding sites. In both cases, we observed high levels of 
H3K4me3 at these Wnt/-catenin–responsive genomic regions 
and a statistically significant reduction when Pygo2 was de-
pleted (Fig. 8 D).
The specific effect of Pygo2 depletion on H3K4me2/3 is 
reminiscent of that seen when core components of SET domain 
HMT complexes are depleted (Wysocka et al., 2005; Dou et al., 
2006). Therefore, we asked whether Pygo2 physically associates 
with WDR5, an essential and common component of SET do-
main HMT complexes (Wysocka et al., 2005). Anti-Pygo2 anti-
body immunoprecipitated WDR5 from 293T cells both in the 
absence and presence of BIO, an inhibitor of intracellular GSK3 
which increases nuclear -catenin levels (Fig. 8 E; Sato et al., 
2004). In contrast, Pygo2 interaction with -catenin was evident 
only when BIO was present. Pygo2–WDR5 interaction was also 
observed in MCF10A cells stably transfected with a Flag-tagged 
Pygo2 protein (Fig. 8 F). Together, these experiments demon-
strate that Pygo2 physically associates with WDR5 and that this 
interaction is likely independent of nuclear -catenin.
To test whether Pygo2 facilitates chromatin association of 
WDR5, we prepared bulk chromatin (Mendez and Stillman, 
2000) from MCF10A cells transfected with Pygo2 or control 
siRNA. Although WDR5 readily associated with the chromatin 
in control cells, little association was detected when Pygo2 was 
depleted (Fig. 8 G). In ChIP experiments, we detected specific 
binding of WDR5 to Wnt/-catenin–responsive regions in the   
c-Myc enhancer and Lef1 promoter and saw that this binding was 
dramatically reduced when Pygo2 was depleted (Fig. 8 H). Simi-
lar findings were made on the cyclin D1 promoter, which is an-
other direct target of Wnt/-catenin (Tetsu and McCormick, 
1999; unpublished data). Therefore, Pygo2 is required for effi-
cient association of WDR5 with bulk chromatin as well as at 
Pygo2/Wnt/-catenin target loci in mammary progenitor cells.
Discussion
In this work, we describe, for the first time, important biological 
and mechanistic functions of chromatin regulator Pygo2 in mam-
mary gland development and regeneration. Although the Drosoph-
ila studies discussed in the Introduction section have previously 
elucidated a genetic connection between Drosophila Pygo and Wg 
signaling, our work provides the first in vivo evidence that Pygo2 
functionally participates in Wnt/-catenin signaling in a mamma-
lian tissue. Although we use mammary cells as a model system, 
these findings are likely applicable to other epithelial tissues that 
require Pygo2 and Wnt/-catenin signaling for their development 
and regeneration.
and Western  blotting  confirmed  the  enriched  presence  of 
H3K4me3 in GST–Pygo2 PHD pull-down samples (Fig. 7 C). 
In coimmunoprecipitation experiments, anti-Pygo2 antibody but 
not control IgG immunoprecipitated H3K4me3 from nuclease-
digested chromatin prepared from cultured cells (Fig. 7 D). 
The ability of Pygo2 PHD to bind to biotinylated histone H3 
N-terminal peptides was also tested. Binding was observed for 
K4 di- and trimethylated peptides, but not for unmethylated   
or K4 monomethylated peptides (Fig. 7 E). Importantly, the 
W352 to A mutation completely abolished Pygo2 binding   
to H3K4me2/3 peptides. In summary, these experiments un-
cover a new molecular function of Pygo2, which is binding 
to H3K4me2 and H3K4me3, two histone marks associated with 
active chromatin.
To delineate further H3K4me2/3-interacting residues in 
Pygo2 PHD, we generated and purified recombinant GST–
Pygo2 PHD fusion proteins containing additional mutations at 
conserved residues and tested them using the native histone-
binding assay. We also tested the ability of these proteins to bind 
to a 6× His–tagged HD1 domain of adapter protein BCL9 
(Townsley et al., 2004). Three classes of mutations were identi-
fied: (1) those affecting both H3K4me2/3 and BCL9 binding 
(W352, M360, and T361), (2) those affecting only H3K4me2/3 
binding (Y327), and (3) those affecting primarily BCL9 binding 
(A364 and L368; Fig. 7 F). Next, we repeated the binding assay 
but this time including a third component. An enhancement in 
PHD–BCL9 (HD1) interaction was observed when histones 
were added (Fig. 7 G, top; compare lanes 6 and 7 with lane 2). 
Moreover, BCL9 HD1 was able to interact with H3K3me3 when 
Pygo2 PHD was present (Fig. 7 G, bottom; compare lane 7 with 
lane 5). These results suggest that Pygo2–H3K4me3 and Pygo2–
BCL9 (thus -catenin) interactions are not mutually exclusive 
but instead are synergistic.
Next, we performed colony formation assay to assess the 
functional importance of Pygo2–H3K4me2/3 interaction. The 
introduction of exogenous full-length Pygo2 to MCF10A cells 
enhanced their colony formation (Fig. 7 H). The Y327A muta-
tion abolished this enhanced colony-forming capacity, whereas 
the L368A mutation had a less detrimental effect. A deletion of 
the PHD led to colony formation at a level even below that 
achieved with vector control, suggesting a dominant-negative 
effect. Therefore, Pygo2 binding to both H3K4me2/3 and BCL9/ 
-catenin is important for its function in mammary progenitor 
cell expansion, with binding to H3K4me2/3 contributing more 
significantly than its previously known interaction with BCL9/ 
-catenin (Townsley et al., 2004).
Pygo2 facilitates H3 K4 trimethylation  
by recruiting WDR5, a core  
component of histone HMT complexes,  
to target chromatin
Next, we asked whether Pygo2 regulates H3 K4 methyla-
tion in MECs. A significant reduction in the level of extract-
able H3K4me3 was observed when Pygo2 was depleted from 
MCF10A cells (Fig. 8 A). At high concentrations of Pygo2 
siRNA, the level of total histone H3 was also reduced; however, 
the decrease in H3K4me3 was quantitatively more remarkable. JCB • VOLUME 185 • NUMBER 5 • 2009   820
Figure 7.  The H3K4me2/3-binding activity of Pygo2 is required for colony formation by mammary progenitor cells. (A) Sequence alignment of PHD 
fingers in Pygo and ING2/bromodomain PHD finger transcription factor (BPTF) proteins. Note that the residues critical for H3K4me3 binding in ING2 and 
bromodomain PHD finger transcription factor (highlighted in red) are conserved among Pygo PHDs. Residues required for BCL9 binding are highlighted in 
blue. The asterisks represent conserved cysteine and histidine amino acids of the C4HC3 PHD. (B) Coomassie blue staining of calf thymus histone pull-downs. 
(C) Western blot analysis of pull-down samples in B with antibodies against mono-, di-, and trimethylated H3 K4. (D) Coimmunoprecipitation/Western blot 
analysis of Pygo2–H3K4me3 interaction in 293T cells. (E) Pull-down of histone H3 N-terminal peptides, with eluates analyzed by Western blotting with   821 PYGO2 IN BREAST PROGENITOR CELLS • Gu et al.
whereas mouse mammary tumor virus (MMTV)–Wnt1 mice 
have an increased number of Lin
CD24
+CD29
High cells in their 
mammary glands (Shackleton et al., 2006). Moreover, loss of 
Pygo2 leads to a decreased K6
+ mammary progenitor population, 
whereas K14-N–-catenin, Cby1 (this study), MMTV-Wnt1, 
and MMTV–-catenin (Li et al., 2003) mice all contain an in-
creased K6
+ population within the mammary epithelium. Second, 
we show that depletion of Pygo2 results in decreased expression 
of both artificial and physiological Wnt/-catenin target genes, 
including BAT-gal, Lef1, c-Myc, and cyclin D1. Third, we dem-
onstrate direct occupancy of Pygo2 at the known target loci.   
Finally and most importantly, we report a complete rescue of the 
Wnt/-catenin–activated aberrant mammary outgrowth by the 
loss of epithelial Pygo2. Collectively, these results lend strong 
support to the notion that Pygo2 regulates the cellular and molec-
ular events downstream of Wnt/-catenin signaling; in its ab-
sence, ectopic Wnt/-catenin signaling can no longer elicit its 
effect on mammary progenitor cells. As such, our work signifi-
cantly extends the current understanding on the role of Wnt/ 
-catenin signaling in mammary stem/progenitor cell self-renewal.
Pygo2 and chromatin-activating histone 
methylation in mammary progenitor cells
While this work was in progress, Fiedler et al. (2008) reported in 
vitro evidence that several Pygo proteins, particularly human 
Pygo1, can directly bind H3K4me2 and H3K4me3. Our work 
now provides independent as well as in vivo evidence that Pygo2 
directly binds to K4-methyl histone H3. That an H3K4me2/3 
binding–deficient Pygo2 protein loses its ability to enhance col-
ony formation strongly suggests that Pygo2 functions in mam-
mary progenitor cell expansion by binding to H3K4me2/3. 
Moreover, we show that Pygo2 not only binds to but also facili-
tates the generation of additional H3K4me3 marks in both bulk 
chromatin and at specific Wnt target loci. This capacity to both 
“read” and “write” (Strahl and Allis, 2000; Fischle et al., 2003) 
H3 K4 methylation highlights the existence of a Pygo2-mediated 
positive feedback to achieve an active chromatin status.
The ability of Pygo2 to facilitate histone H3 trimethylation 
likely arises from its physical association with SET domain 
HMT complexes, as suggested by the observed Pygo2–WDR5 
interaction in mammary progenitor cells. Interestingly, this inter-
action occurs in the absence of extracellular Wnt-like stimuli and 
independently of detectable Pygo2–-catenin interaction. Con-
sistently, we show that Pygo2 depletion results in decreased 
WDR5 occupancy and H3K4me3 not only at Wnt/-catenin tar-
get loci but also in bulk chromatin in unstimulated mammary 
progenitor cells. Based on these results, we surmise that Pygo2 
is bound to chromatin and facilitates H3 K4 trimethylation in the 
Pygo2, mammary progenitor cell expansion, 
and cell cycle control
Early embryonic mammary progenitor cells switch from a dor-
mant to an actively expanding state during the bud to sprout 
transformation (Veltmaat et al., 2003). Although stem cells in a 
homeostatic adult tissue are presumably quiescent (Chepko and 
Smith, 1997; Woodward et al., 2005), expansive self-renewal of 
mammary stem/progenitor cells is essential during postnatal de-
velopment and for regeneration to occur after transplantation 
(Smith, 2005). Our study identifies Pygo2 as a novel biomarker 
of expanding mammary progenitor cells. More importantly, our 
parallel analysis of conventional and tissue-specific Pygo2-null 
mutant mice demonstrates that both embryonic progenitor cell 
proliferation  and  postnatal  progenitor  cell  expansion  require 
Pygo2.  Thus,  at  least  some  common  regulatory  circuits  are 
shared by embryonic and postnatal mammary progenitor cells. 
That said, mammary morphogenesis and regeneration are crip-
pled but not abolished in the absence of Pygo2, leaving open the 
possibility of functional redundancy from Pygo1.
How does Pygo2 facilitate progenitor cell expansion?   
Molecular mechanisms, including the use of cell cycle inhibitors 
such as p21, exist to prevent quiescent stem cells from entering 
active cell cycle in bone marrow, skin, and forebrain (Topley   
et al., 1999; Cheng et al., 2000; Kippin et al., 2005). Indeed, p21 
expression is enriched in a subset of label-retaining mammary 
cells (Clarke, 2005; Clarke et al., 2005). Conceivably, for expan-
sive self-renewal to occur, stem/progenitor cells must possess 
the ability to counteract cell cycle inhibition. We found that loss 
of Pygo2 leads to a G1 stall of the cell cycle, accompanied by 
decreased c-Myc and cyclin D1 expression as well as increased 
p21 expression. These results suggest that Pygo2 empowers 
mammary stem/progenitor cells with the capacity to expand by 
directly or indirectly regulating critical cell cycle genes, thereby 
promoting G1–S transition.
Pygo2 and Wnt signaling in  
mammary epithelium
We have extensively probed into the involvement of mammary 
epithelial Pygo2 in Wnt signaling using both mouse models and 
molecular analyses. First, we uncover a mammary phenotype in 
Pygo2-deficient  mice  that  is  consistent  with  loss  of  Wnt/ 
-catenin signaling. The differential impairment of Pygo2
/ mam-
mary rudiments is reminiscent of mammary placodes 2 and 3 
suffering most severely from a homozygous Lef1-null mutation 
(van Genderen et al., 1994; Boras-Granic et al., 2006; unpub-
lished data). The morphological defects of Pygo2 SSKO mice are 
similar to those of mice deficient for Lrp5, a Wnt coreceptor 
(Lindvall et al., 2006). Pygo2 SSKO mice have a decreased, 
anti-GST antibody. (F) Mapping residues in Pygo2 PHD required for H3K4me3 (b) or BCL9 HD1 (c) interaction. (a) Coomassie blue staining of GST, GST–
Pygo2 PHD derivatives, and 6× His–BCL9 HD1 domain proteins purified from bacteria. GST pull-downs of histones were analyzed by Western blotting 
with anti-H3K4me3 (b), whereas nickel (6× His) pull-downs of GST-PHD derivatives were analyzed with anti-GST antibodies (c). (G) Synergistic interactions 
among H3K4me3–Pygo2–BCL9. Purified proteins were incubated as indicated and pulled down by nickel beads, and eluates were analyzed by Western 
blotting with the indicated antibodies. (H) Methyl histone H3 binding of Pygo2 is required for colony formation by MCF10A cells. (a) Representative   
images revealing the effects of exogenous Pygo2 derivatives are shown. (b) Quantification of three independent experiments. Error bars represent standard 
deviation. *, P = 1.0; **, P = 0.045; ‡, P = 0.010; and †, P = 0.030. P-values were calculated using two-tailed t tests assuming equal variance. Note that 
wild-type and mutant 2× Flag–flagged Pygo2 proteins were expressed at similar levels in infected cells (c). IB, immunoblot; IP, immunoprecipitation.
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Figure 8.  Pygo2 regulates H3K4me3 levels by facilitating chromatin association of WDR5. (A) Requirement of Pygo2 for global H3K4me3 in MCF10A 
cells. The H3K4me3/H3 ratio in cells treated with 30 nM of control siRNA was arbitrarily set to be 1. (B) Western blot analysis showing that Pygo2 
knockdown specifically affects di- and trimethylation of H3 K4. (C) Reduced H3K4me3 levels in Pygo2 SSKO mammary glands. The H3K4me3/H3 ratio 
in wild-type glands was arbitrarily set to be 1. (D) Results of ChIP experiments revealing reduced H3K4me3 at the c-Myc enhancer and Lef1 promoter. 
Note that the total H3 levels at these loci are not significantly affected. (E) Association of Pygo2 with WDR5 in 293T cells with and without BIO treatment. 
(F) Pygo2–WDR5 interaction in MCF10A cells. Asterisks label cross-reacting IgGs. (G) Reduction of chromatin association of WDR5 upon knockdown of 
Pygo2 in MCF10A cells. The asterisk indicates a cross-reacting band. WCE, whole-cell extract; S2, soluble cytosolic fraction; S3, soluble nuclear fraction; 823 PYGO2 IN BREAST PROGENITOR CELLS • Gu et al.
lines (Andrews et al., 2007; unpublished data). Based on our 
loss of function data, it is reasonable to expect altered p21 ex-
pression in Pygo2-overexpressing cancer cells. Indeed, loss of 
p21 accelerates ras-induced mammary tumorigenesis (Adnane 
et al., 2000) and appears to be the underlying basis for hormon-
ally responsive breast cancer cells to develop tamoxifen resis-
tance (Abukhdeir et al., 2008). In the future, it will be worthwhile 
to directly explore the involvement of Pygo2 in stem/progenitor-
derived breast cancers and cancer stem cells.
Currently, drugs that aim at correcting silencing epige-
netic changes at select tumor suppressor loci are being tested in 
clinical trials for cancer therapy (Yoo and Jones, 2006). How-
ever, it had not been appreciated that such drugs may activate 
chromatin in an undesired manner that sets off uncontrollable 
normal as well as cancer stem cell expansion. The study of how 
normal activating epigenetic patterns are established and main-
tained in stem/progenitor cells and how alterations occur in can-
cer bears important implications on cancer therapy.
Materials and methods
Mice and antibodies
The generation and genotyping of null and floxed Pygo2 alleles were per-
formed as previously described (Li et al., 2007). Pygo2
/ embryos were 
obtained by Pygo2
+/ heterozygote intercrosses. Pygo2 SSKO mice were 
generated by crossing K14-Cre/Pygo2
+/ males with Pygo2
flox/flox or   
Pygo2
flox/+ females. To confirm tissue-specific recombination, the epidermis 
was separated from the underlying dermis by overnight exposure of new-
born back skin to dispase II (Roche) at 4°C as previously described (Kitano 
and Okada, 1983), and DNAs were prepared from isolated epidermis and 
dermis for genotyping. Sex was determined by PCR of a male-specific gene 
using the primers 5-TTACATAATCACATGGAGAGCCA-3 and 5-GTCA-
CATTTATGAGGATACGCC-3. Estrus was determined by established mor-
phological criteria. K14-N–-catenin and BAT-gal mice were gifts from   
E. Fuchs (The Rockefeller University, New York, NY) and S. Piccolo (University 
of Padova, Padova, Italy). All experiments have been approved by and 
conform to the regulatory guidelines of the International Animal Care and 
Use Committee of the University of California, Irvine.
-Pygo2 rabbit polyclonal antibody was previously described (Li et al., 
2007). Antibodies to K14 (chicken; 1:4,000), K6 (rabbit; 1:500), and 
GATA-3 were gifts from J. Segre (National Institutes of Health, Bethesda, 
MD). -NKCC1 was a gift from J. Turner (National Institutes of Health, 
Bethesda, MD). Other antibodies were obtained commercially: -ER (MC-20; 
Santa Cruz Biotechnology, Inc.); -K18 (Developmental Studies Hybridoma 
Bank); -H3, -H3K4me1, -H3K4me2, -H3K4me3, -H3K9me3, and   
-H3K27me3  (Millipore);  -Flag  and  –-catenin  (Sigma-Aldrich);   
-WDR5 and –-actin (Abcam); and rabbit IgG and -GST (Santa Cruz 
Biotechnology, Inc.).
Morphology, immunostaining, and whole-mount in situ hybridization
For whole-mount mammary gland staining, E18.5 skins were flattened on 
microscope slides, fixed overnight in Carnoy’s solution (75% ethanol and 
25% acetic acid), and stained with carmine alum as previously described 
(Sympson et al., 1994). Postnatal mammary glands were fixed in 60%   
ethanol, 30% CHCl3, and 10% glacial acetic acid and similarly stained.
Indirect immunofluorescence was performed as previously described 
(Dai et al., 1998) using rabbit -Pygo2 antiserum that was preadsorbed with 
tissue powder prepared from E15.5 Pygo2
/ embryos. FITC-conjugated 
goat anti–rabbit and rhodamine-conjugated goat anti–chicken or mouse 
secondary antibodies (Jackson ImmunoResearch Laboratories) were used, 
and slides were mounted in antifade medium (Vectashield H-1000; Vector 
Laboratories). Images were taken at room temperature with an inverted   
fluorescence microscope (Eclipse E600; Nikon) using Plan-Apochromat 
absence of Wnt signaling, providing a molecular basis for Wnt/ 
-catenin–independent biological functions of Pygo2 (Song et al., 
2007; Nair et al., 2008). However, in Wnt-stimulated cells, simul-
taneous and synergistic interactions between Pygo2, H3K4me2/3, 
and BCL9/-catenin at Wnt target promoters may significantly 
alter the free energy required for assembly of a macromolecular 
complex to bring about maximal transcriptional activation. In this 
way, Wnt signaling exploits Pygo2, a rather nonspecific chroma-
tin effector to achieve maximal activation of specific target genes. 
That a global chromatin regulator regulates transcriptional output 
of a specific gene set is not unprecedented. For instance, although 
it has been well documented that WDR5 depletion dramatically 
affects global H3K4me3 levels (Wysocka et al., 2005), during   
osteoblast differentiation, WDR5 overexpression/depletion results 
in increased/decreased Wnt target gene expression, respectively 
(Zhu et al., 2008).
Although our data provide an underlying mechanism for a 
Wnt signaling coactivator function of Pygo proteins, we have not 
been able to obtain evidence supporting a role for Pygo2 in   
-catenin nuclear localization in mammary progenitor cells. Few 
cells in developing mammary glands express nuclear -catenin, 
making it difficult to convincingly demonstrate any possible   
reduction of such cells in Pygo2-deficient mice. We performed 
Western blot analysis on nuclear extracts isolated from MCF10A 
cells and those depleted for Pygo2 but failed to detect any signifi-
cant decrease in the level of Wnt-stimulated nuclear -catenin 
(unpublished data). Therefore, the function of Pygo2 in nuclear 
retention of -catenin might be cell type dependent.
Chepko and Smith (1997) noted that the heterochromatin in 
mammary stem cells is lost in early progenitor cells but reappears 
in differentiated cells, demonstrating a correlation between open 
chromatin configuration and a mammary progenitor fate. Our 
findings now imply a causal link between Pygo2-facilitated chro-
matin activation and mammary progenitor cell expansion. Em-
bryonic stem cells are also capable of expansive self-renewal, and 
their chromatin is indeed mostly open, as suggested by the abun-
dance of H3K4me3 and acetylated histone H4 (also associated 
with active chromatin) and scarcity of K9 or K27 trimethylated 
histone H3 (Niwa, 2007). Therefore, a globally active chromatin 
conformation may be a key feature of expanding stem/progenitor 
cells, and the epigenetic function of Pygo2 in different stem/ 
progenitor cell systems merits further investigation.
Relevance to breast cancer
The number of stem/progenitor cells in a given tissue is thought to 
be determined during critical developmental windows (Ginestier 
and Wicha, 2007). It follows that if breast cancer stem cells 
arise from normal mammary stem/progenitor cells, the number 
of cells that can serve as transformation targets may dictate can-
cer risk. In this context, Pygo2 may be a potential target of 
mammary tumorigenesis, particularly in cancers that are of a 
stem/progenitor cell origin. Consistent with this notion, Pygo2 
expression is up-regulated in breast cancers and cancer cell 
P3, chromatin-enriched fraction. (H) ChIP analysis showing decreased WDR5 occupancy at the c-Myc enhancer and Lef1 promoter in Pygo2-depleted 
MCF10A cells. (D and H) Error bars represent standard deviation. IB, immunoblot; IP, immunoprecipitation.
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Triton X-100, and 0.05% Tween 20) containing 10% goat serum for   
45–60 min at room temperature, after which indirect immunofluorescence 
was performed as described in Morphology, immunostaining, and whole-
mount in situ hybridization.
MCF10A cells, human embryonic kidney 293T cells, and packag-
ing 293GP2 cells were cultured as previously described (Furuta et al., 
2006). The PHD of Pygo2 and HD1 domain of BCL9 were cloned by PCR 
from Pygo2 cDNA and cDNAs of human HaCaT cells, respectively. Point 
mutations were generated by site-directed mutagenesis (Agilent Technolo-
gies). DNA fragments were subcloned into pGEX4T-3 (GE Healthcare),   
pRSET-A (Invitrogen), pcDNA3.1–2× Flag, and pQCXIP (BD) for expres-
sion in bacteria or mammalian cells.
Protein purification and pull-down assays
GST- or 6× His–tagged fusion proteins were expressed in BL21(DE3)/pLysS 
strain and purified to near homogeneity as previously described (Shang   
et al., 2003). Fusion proteins were eluted with 10 mM glutathione or 200 mM 
imidazole where necessary. Purified calf thymus core histones (Worthing-
ton) were incubated with purified GST fusion proteins bound on beads for 
3 h at 4°C. Up to 5 µg of histones and 10 µg of GST fusion proteins were 
used in each pull-down reaction. Beads were washed four times with bind-
ing buffer containing 50 mM Tris, pH 7.4, 300 mM NaCl, 0.5 mM EDTA, 
0.5% NP-40, 1 mM PMSF, and protease inhibitors cocktail (Roche). Bound 
proteins were boiled with 2× sample buffer and analyzed by SDS-PAGE/
Western blotting. For peptide pull-downs, 1 µg of biotinylated histone pep-
tides (Millipore) were incubated with 1 µg of GST fusion proteins in bind-
ing buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% NP-40, 1 mM PMSF, 
and protease inhibitor cocktail) overnight at 4°C. After 1 h of incubation, 
streptavidin beads (Thermo Fisher Scientific) were washed three times and 
subjected to Western blot analysis. For binding assays between BCL9-HD1 
and  GST  fusion  proteins,  6×  His–HD1  were  incubated  with  an  equal 
amount of GST–Pygo2 PHD derivatives in binding buffer containing 10 mM 
imidazole, and protein complexes were captured by nickel–nitrilotriacetic 
acid beads (QIAGEN).
Coimmunoprecipitation and Western blotting
Cells were either untreated or treated with 2 µM BIO (Sigma-Aldrich) for 
2 h in culture media, and nuclear extracts were prepared with treatment 
of benzonase (EMD) as previously described (McKinnell et al., 2008). Pri-
mary antibody of -Pygo2 or control normal rabbit IgG was incubated at 
2 µg per 500 µg of nuclear extract overnight at 4°C before being col-
lected  with  protein  A/G  beads.  Immunocomplexes  were  washed  four 
times with nuclear lysis buffer and eluted by boiling in 2× sample buffer. 
Samples were resolved by 12% SDS-PAGE and immunoblotted with the in-
dicated antibodies.
Retroviral infection and colony formation assay
Recombinant retrovirus expressing 2× Flag–Pygo2 derivatives were gener-
ated as previously described (Wang et al., 2007). In brief, packaging cells 
293GP2 were cotransfected with pVSV-G and a retroviral vector pQCXIP 
expressing 2× Flag–Pygo2 derivatives. Titered viruses were then used to 
infect MCF10A cells for 48 h before selection with 2.5 µg/ml puromycin 
for an additional 48 h. The pool of infected cells was then counted and plated 
at 1,000 cells per 60-mm dish in triplicate in the presence of 0.4 µg/ml   
puromycin. After 2 wk, colonies were fixed, stained with methyl blue, and 
counted as previously described (Chen et al., 1999).
ChIP and chromatin fractionation
MCF10A  cell  were  transfected  with  Pygo2  siRNA  or  negative  control 
siRNA (Applied Biosystems) using Lipofectamine 2000 (Invitrogen) accord-
ing to manufacture’s instructions. Cells were harvested 72 h after trans-
fection and were either lysed in sample buffer for Western blot analysis or 
fixed in 1% formaldehyde for subsequent ChIP analysis according to the 
protocol from Millipore. Real-time PCR quantification of ChIP signals was 
performed in triplicate using SYBR Green Supermix (Bio-Rad Laboratories) 
and primers for c-Myc enhancer (Sierra et al., 2006) or Lef1 promoter (for-
ward, 5-TCCTGGATTCCTTCACCAAC-3; reverse, 5-TCAGGCTGCTGA-
ACATTGAA-3). ChIP signals were quantified relative to normal IgG or 
control histone H3 signals where indicated.
Biochemical chromatin fractionation was performed as previously 
described (Mendez and Stillman, 2000). MCF10A cells were transfected 
with Pygo2 or control siRNA for 72 h and harvested for preparation of   
either whole cell extract or fractions enriched for cytoplasmic, nuclear solu-
ble, or chromatin. Protein samples were analyzed by Western blotting with 
specific antibodies as indicated.
20× NA 0.75 or Plan-Fluor 40× NA 0.75 objectives (Nikon) and a cam-
era (RT Slider; Diagnostic Instruments, Inc.) equipped with SPOT 4.0.9 soft-
ware (Diagnostic Instruments, Inc.). Acquired images were processed by 
Photoshop CS 8.0 (Adobe).
Whole-mount in situ hybridizations were performed as previously 
described (Mackay et al., 2006) using a Wnt10b probe (Veltmaat et al., 
2004) or a 710-bp fragment corresponding to nucleotides 1,034–1,743 
of  Lef1  mRNA  (GenBank/EMBL/DDBJ  accession  no.  NM_010703).   
Images were acquired using an Eclipse E600 microscope.
Analysis of -galactosidase expression
Analysis of BAT-gal expression was performed as previously described (Li 
et al., 2007). 10-µm transverse cryosections were counterstained with Nu-
clear Fast red. -Galactosidase staining of adult mammary glands was 
performed as follows: 14-µm sections were fixed in 0.5% glutaraldehyde 
in 0.1 M phosphate buffer for 2 min, washed with 0.1 M phosphate buffer 
eight times, and transferred into freshly prepared X-gal staining solution 
containing 100 mM Na-phosphate buffer, pH 7.3, 1 mg/ml X-gal, 3 mM 
K3Fe(CN)6, 3 mM K4Fe(CN)6, and 1.3 mM MgCl2. Incubation was per-
formed at room temperature in the dark until signal appeared. The slides 
were subsequently counterstained with Nuclear Fast red and mounted with 
the Permount mounting medium (Thermo Fisher Scientific).
FACS analysis
Mammary glands from 10–12-wk-old virgin females were digested for 6 h 
at 37°C in RPMI 1640 containing 5% FBS, 300 U/ml collagenase, and 
100 U/ml hyaluronidase. After vortexing and lysis of the red blood cells in 
NH4Cl, a single-cell suspension was obtained by sequential dissociation of 
the fragments by gentle pipetting for 1–2 min in 0.25% trypsin and then for 
2 min in 5 mg/ml dispase II plus 0.1 mg/ml DNase I (Sigma-Aldrich) fol-
lowed by filtration through a 40-mm mesh. Staining was performed using 
the following antibodies and reagents: biotinylated CD31 (BD), biotinyl-
ated CD45 (BD), biotinylated TER119 (BD), streptavidin-allophycocyanin 
(BD),  phycoerythrin  Rat  IgG2b,    isotype  control  (BD),  FITC  Armenian 
Hamster IgG isotype control (BioLegend), CD24-phycoerythrin (BD), and 
CD29-FITC (BioLegend). Cell cycle analysis was performed as previously 
described (Gu and Chen, 2009). Cells were acquired on FACSCalibur 
(BD), and analysis was performed using FlowJo (Tree Star, Inc.).
Limiting dilution cell transplantation
Limiting dilution cell transplantation was performed essentially as previously 
described (Moraes et al., 2007). In brief, primary MECs isolated from two 
paired sets of control or Pygo2 SSKO mice (three mice per genotype per set) 
were counted and resuspended in a 1:1 solution of PBS/Matrigel (BD). Cells 
of each genotype were injected at limiting dilutions (10,000, 5,000, 1,000, 
500, and 250 cells per gland, in a total volume of 10 µl) into contralateral 
cleared fat pads of no. 4 mammary glands of 21-d-old female severe com-
bined immunodeficiency Beige mice (Charles River Laboratories) using a   
25-G needle attached to a 50-µl Hamilton glass syringe. 8–9 wk after trans-
plantation, no. 4 glands were excised and stained as whole mounts. Glands 
showing at least 5% fat pad filling were scored as a positive take. Statistical 
analysis of the take rate was performed as previously described (Moraes   
et al., 2007). The data on fat pad filling were analyzed by a generalized 
linear model using the Gamma regression.
BrdU labeling and immunodetection
Pregnant mice were intraperitoneally injected with 50 µg/g body weight 
of BrdU in PBS. Embryos were taken 1 h after injection, cryosectioned at 
10 µm, and fixed in 4% paraformaldehyde for 10 min followed by immuno-
histochemistry as previously described (Li et al., 2005). A weak hema-
toxylin counterstaining was performed, and cells within each mammary 
bud were counted to determine the percentage of BrdU-positive cells versus 
the total number of cells. Statistical significance was determined using Stu-
dent’s t test.
Cell culture, cloning, and mutagenesis
Primary MECs (2 × 10
4) isolated from 8–10-wk-old virgin females were 
plated on Matrigel (BD) per well in chamber slides (Laboratory-Tek II), cul-
tured for 14 d, and fixed in 4% paraformaldehyde for 20 min at room tem-
perature. Colonies were then permeabilized with PBS containing 0.5% 
Triton X-100 for 10 min at 4°C, followed by three 10–15-min rinses with 
PBS/glycine (130 mM NaCl, 7 mM Na2HPO4, and 3.5 mM NaH2PO4; 
100  mM  glycine)  at  room  temperature.  Nonspecific  interactions  were 
blocked by incubating with 200 µl/well of IF buffer (130 mM NaCl, 7 mM 
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